Article ID Journal Published Year Pages File Type
6190955 Clinical Radiology 2015 8 Pages PDF
Abstract

•Various treatments are being used in recanalization of basilar artery occlusion.•Multimodal endovascular treatment is an effective recanalization method.•Time-to-treatment is the only modifiable outcome predictor.•Bridging therapy shortens time-to-treatment.•Arterial hypertension, neurologic deficit are associated with poor outcome.

AimTo evaluate the safety and efficacy of multimodal endovascular treatment (EVT) of acute basilar artery occlusion (BAO), including bridging therapy [intravenous thrombolysis (IVT) with subsequent EVT], to compare particular EVT techniques and identify predictors of clinical outcome.Materials and methodsThis retrospective, multi-centre study comprised 72 acute ischaemic stroke patients (51 males; mean age 59.1 ± 13.3 years) with radiologically confirmed BAO. The following data were collected: baseline characteristics, risk factors, pre-event antithrombotic treatment, neurological deficit at time of treatment, localization of occlusion, time to therapy, recanalization rate, post-treatment imaging findings. Thirty- and 90-day outcomes were evaluated using the modified Rankin scale with a good clinical outcome defined as 0-3 points.ResultsSuccessful recanalization was achieved in 94.4% patients. Stepwise binary logistic regression analysis identified the presence of arterial hypertension (OR = 0.073 and OR = 0.067, respectively), National Institutes of Health Stroke Scale (NIHSS) at the time of treatment (OR = 0,829 and OR = 0.864, respectively), and time to treatment (OR = 0.556 and OR = 0.502, respectively) as significant independent predictors of 30- and 90-day clinical outcomes.ConclusionData from this multicentre study showed that multimodal EVT was an effective recanalization method in acute BAO. Bridging therapy shortens the time to treatment, which was identified as the only modifiable outcome predictor.

Related Topics
Health Sciences Medicine and Dentistry Oncology
Authors
, , , , , , , , , , , , , , , , ,